The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Open accessAbstract
The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Sharma, A., Tiwari, S., Deb, M. K., & Marty, J. L. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106054 · Cited by 705
New insights into the antiviral effects of chloroquine
Savarino, A., Di Trani, L., Donatelli, I., Cauda, R., & Cassone, A. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70361-9 · Cited by 570
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388
Coleman, C. M., Sisk, J. M., Mingo, R. M., Nelson, E. A., White, J. M., & Frieman, M. B. (2016) · Journal of Virology · doi:10.1128/jvi.01429-16 · Cited by 257
Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies
Costa, F. F., Rosário, W. R., Farias, A. C. R., de Souza, R. G., Gondim, R. S. D., & Barroso, W. A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.06.016 · Cited by 147
COVID-19: from epidemiology to treatment
Pericàs, J. M., Meneses, M. H., Sheahan, T. P., Quintana, E., Ambrosioni, J., Sandoval, E., Falces, C., Marcos, M. Á., Tuset, M., Vilella, A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa462 · Cited by 115
SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping
Kaur, G., Lungarella, G., & Rahman, I. (2020) · Journal of Inflammation · doi:10.1186/s12950-020-00250-8 · Cited by 102
Azim, K. F., Ahmed, S. R., Banik, A., Khan, M. M. R., Deb, A., & Somana, S. R. (2020) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2020.100367 · Cited by 76
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19
Homolak, J., & Kodvanj, I. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106044 · Cited by 74
Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Favilli, A., Gentili, M. M., Raspa, F., Giardina, I., Parazzini, F., Vitagliano, A., Borisova, A. V., & Gerli, S. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2020.1774875 · Cited by 57
Su, B., Wang, Y., Zhou, R., Jiang, T., Zhang, H., Li, Z., Liu, A., Shao, Y., Hua, W., Zhang, T., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01472 · Cited by 44
Pandeya, K. B., Ganeshpurkar, A., & Mishra, M. K. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109905 · Cited by 40
Tsitoura, E., Bibaki, E., Bolaki, M., Vasarmidi, E., Trachalaki, A., Symvoulakis, E. K., Spandidos, D. A., & Antoniou, K. M. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8692 · Cited by 11
Clinical interventions for severe and critical COVID-19: what are the options.
Yuan, W., Liu, S., Lu, L., Feng, J., & He, X. (2020) · PubMed Central · Cited by 7
Research works printed but not linked: 1
- 17. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. 2020.2001.2031.929042. · DOI
Cited by
The Fear of COVID-19 Scale: Development and Initial Validation
Ahorsu, D. K., Lin, C.-Y., Imani, V., Saffari, M., Griffiths, M. D., & Pakpour, A. H. (2022) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-020-00270-8 · Cited by 4,332
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14817 · Cited by 3,559
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Metadata
- Authors
- Dong, L., Hu, S., & Gao, J.
- Venue
- Drug Discoveries & Therapeutics
- Publisher
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
- Published
- 2020-02-29
- Volume
- 14
- Issue
- 1
- Pages
- 58-60
- ISSN
- 1881-7831 (ISSN-L)
- 1881-784X
- OpenAlex
- W3009828946
- Cited by
- 1,390
- References
- 21
- FWCI
- 40.20
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.